| Title | Severe cardiomyopathy following treatment with the tumour necrosis factor-alpha inhibitor adalimumab for Crohn's disease. | | Author(s) | Emmert MY, Salzberg SP, Emmert LS, Behjati S, Plass A, Felix C, Falk V, Gruenenfelder J | | Institution | Department of Cardiovascular Surgery, University Hospital Zurich, 8091 Zurich, Switzerland. maximilian_emmert@web.de | | Source | Eur J Heart Fail 2009 Nov; 11(11):1106-9. | | Abstract | Adalimumab belongs to the group of tumour necrosis factor-alpha inhibitors and has been approved for the treatment Crohn's Disease since 2007. Herein we report a severe adverse reaction to adalimumab in a 25-year-old female patient. One week after the initial-dose of adalimumab (160 mg), which was initiated due to an acute exacerbation of Crohn's disease, the patient developed a fulminant cardiomyopathy. In severe cardiogenic shock, the patient required an extracorporeal membrane-oxygenation system for 8 days until cardiac recovery. | | Language | eng | | Pub Type(s) | Journal Article
| | PubMed ID | 19875411 |
|
